On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
On The Pen With Dave Knapp
On The Pen Live Eps 67: Survodutide Trial Participant Tells All!
In this week’s episode of On The Pen Live, guest Scott Liberto of PlanetScott.com joins to discuss his experience in the Survodutide clinical trial.
Survodutide is an investigational dual agonist targeting both the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim in collaboration with Zealand Pharma. This novel drug is designed to treat obesity and metabolic dysfunction-associated steatohepatitis (MASH).
DNF10 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP
USE CODE "OTP10" to save 10%. A small commission is paid back to support On The Pen!
MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro
BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join
👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen
MORE COMMUNITY!
📺 Watch Our Weekly Live Show: onthepen.tv
🆕 Discord: https://discord.gg/u4Ea8qqP
🤝 Visit Our Sponsor!
GLP-1 Ro Body Plan: https://www.ro.co/otp
Report The Shortage: https://www.ro.co/supply-tracker
Does your insurance cover GLPs? https://www.ro.com/checker
📲 Contact Me: dave@onthepen.com
Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepe...
